Trial Profile
The Clinical Response Evaluation of the Medtronic Endeavor CR ABT-578 Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Zotarolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms RESOLUTE-First in Human
- 19 Oct 2011 Actual end date (Oct 2011) added as reported by ClinicalTrials.gov.
- 23 Sep 2010 Four-year results were presented at the 2010 Transcatheter Cardiovascular Therapeutics (TCT) conference, according to a Medtronic media release.
- 21 Sep 2010 3-year long-term results were presented at the 22nd Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics.